ClinicalTrials.gg
RecruitingNCT07423273Updated Apr 17, 2026

Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression

An interventional study of hyperbaric oxygen therapy in Post Stroke Depression, sponsored by Assaf-Harofeh Medical Center. Recruiting at 1 site in Israel. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Assaf-Harofeh Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2023, registered Apr 2024).
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Depression with a site in Israel — 8 open to participants now, 10 under way, none of them phase 3. Depression · Israel.

Planned enrollment
15th of 56
142 · median 60
Started
2023
with 1 other
No phase
37 of 72
7 open now
Registered
63rd of 72
by date

Among the 72 studies in Depression with a site in Israel, this one is the 15th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2023, is one of 37 with no phase, and was the 63rd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

8 of the 72 studies in Depression with a site in Israel are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Depression with a site in Israel, or all of them as a file.
02

Study summary

The study evaluates the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.

Read the detailed description

Post-stroke depression (PSD) is a prevalent mental health complication, affecting approximately 33% of stroke survivors. Its occurrence not only hinders rehabilitation and recovery from motor and cognitive deficits post-stroke but also escalates the risk of subsequent neurovascular events. Both biological and psychological factors are instrumental in the onset of PSD.

Ischemia plays a pivotal role in the development of long-term PSD due to its impact on specific brain regions, neurotransmitter systems, neural connectivity, inflammatory responses, and mitochondrial dysfunction.

brain ischemia can instigate a protracted cycle of inflammation, levels and functions of neurotransmitters, impaired mitochondrial function, that directly impinges on the brain's ability to undergo neuroplastic changes. This relationship underscores the importance of targeting the cure of brain ischemia in therapeutic strategies for PSD. Managing the brain ischemia could potentially salvage neuroplasticity and mitigate the mental and cognitive decline associated with PSD.

The new protocols of hyperbaric oxygen therapy (HBOT), using the hyperoxic-hypoxic paradox (HHP), is one of the first therapeutic intervention already in clinical use today for the specific goal of inducing regeneration of damaged brain tissue.

Cumulative data from recent years provide convincing evidence that HBOT can induce neuroplasticity leading to repair of chronically impaired brain functions and improved quality of life in post-stroke patients.

Both neurological and cognitive functions were improved even years after the stroke.

The observed restoration of neuronal activity in the metabolically dysfunctional stunned areas indicates that HBOT is a potent means of delivering sufficient oxygen needed for activation of neuroplasticty and restoration of impaired functions.

HBOT was found to be effective in small clinical trials for patients suffering from post-stroke depression. In a meta-analysis done by Liang et al. the efficacy and safety of HBOT for PSD was evaluated. A total of 27 RCTs involving 2250 participants were identified. Patients in HBOT group had a higher response rate than patients in control group (response rate: 69.4% vs 51.2%, odds ratio [OR] = 2.51, 95% confidence interval [CI] [1.83-3.43], P = 0.000). HBOT significantly reduced Hamilton Depression (HAMD).

The aim of the current study is to evaluate the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.

03

Conditions studied

  • Post Stroke Depression

Keywords

  • hyperbaric oxygen therapy
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 50 -85
  2. Suffered an ischemic stroke 6 months to 7 years prior to their inclusion
  3. Treated or being treated by antidepressants for at least 3 months
  4. Diagnosis of PSD based on HDRS-17 score of 17 and above.
  5. Stable psychological and pharmacological treatment for more than three months prior to inclusion.
  6. Subject willing and able to read, understand and sign an .

Exclusion criteria

Exclusion Criteria:

  1. Inability to attend scheduled clinic visits and/or comply with the study protocol
  2. Diagnosis of a psychiatric disorder prior to the recent stroke including: major depression, schizophrenia or bipolar disease.
  3. Diagnosis of aphasia or major cognitive decline
  4. History of Deep brain stimulation (DBS)
  5. History of traumatic brain injury, brain tumors, brain surgery, chronic subdural haemorrhages, Epilepsy
  6. Active
  7. Substance use at baseline.
  8. History of other neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Lewy body dementia (LBD), Frontotemporal dementia (FTD), Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Creutzfeld Jacob disease (CJD), Multisystem atrophy (MSA), Pseudobulbar palsy (PSP), Corticobasal degeneration (CBD), Wernicke Korsakoff syndrome
  9. Serious suicidal ideation
  10. Renal or liver insufficiency, electrolyte imbalances
  11. Chronic heart failure with of 30 or less
  12. HBOT for any reason prior to study enrolment
  13. Chest pathology incompatible with pressure changes (including active asthma or )
  14. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year)
  15. An inability to perform an awake brain MRI
  16. No evidence of vascular related lesions in the brain MRI
  17. Active smoking
  18. Participation in another study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (estimated)

Study arms

  • Active comparator
    hyperbaric oxygen therapy (HBOT) active treatment

    The HBOT protocol consists of 60 daily sessions, five times per week, within a three months' period. Then there will be a follow-up period for 3 months without any investigated intervention. each session lasting 90 minutes, of 100% oxygen at 2 ATA and 5-minute air breaks every 20 minutes.

    Device: hyperbaric oxygen therapy

  • Sham comparator
    Sham hyperbaric oxygen therapy (HBOT) Sham treatment

    All the conditions provided in the HBOT intervention will be provided in the sham intervention. However, in contrast to the HBOT, each session includes breathing 21% oxygen by mask while in the same multiplace chamber. SHAM pressure will go up to 1.2 ATA during the first five minutes of the session (to simulate the pressure sensation in the ears), and then decrease during the next 5 minutes to 1.03 ATA for 90 minutes with 5-minute air breaks, every 20 minutes The initial 1.2 ATA level will provide a minimal pressure sensation in the ears, with the same nurse advice on pumping the ears. In the last five minutes of the session, the air will be circulated again with its related noises. Sham and HBOT sessions will never be adjacent, so subjects from the two groups cannot meet and discuss the session and its effects.

    Device: hyperbaric oxygen therapy

Interventions

  • Devicehyperbaric oxygen therapy

    The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes. Investigational product: Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel.

06

What researchers measure

Primary outcomes

  1. PSD symptoms

    Depression severity will be evaluated by structured interview based on the HDRS-17 guided structural questioner (Hamilton Depression Rating Scale from 0-53 ,Levels of depression is categorized according to the following accepted criteria: * Not depressed: 0-7 * Mild (subthreshold): 8-13 * Moderate: 14-18 * Severe: 19-22 * Very severe: \>23)

    Time frame: Change from Baseline immediately after the intervention

Secondary outcomes

  1. depression

    Beck depression inventory II. Each answer is scored on a scale value of 0 to 3 . The score ranges between 0 and 63, with higher scores indicating more severe depression symptoms.

    Time frame: Change from Baseline immediately after the intervention

  2. Short form health survey (sf-36)

    Quality of life questionnaire, scale of 0-100, higher score means better outcome

    Time frame: at baseline, 3 months, 6 months

  3. psychological distress

    The Brief Symptom Inventory-18 (BSI-18). self-report questionnaire which generates a summary scale, the global stress index (GSI), and three subscales: depression, anxiety, and somatization. Each item is rated on a 5-point scale, with distress ratings ranging from 0 (not at all) to 4 (extremely) .

    Time frame: Change from Baseline immediately after the intervention

  4. health status

    Changes will be measured by The Stroke Impact Scale (SIS). The SIS version 3.0 includes 59 items, An extra question on stroke recovery asks that the client rate on a scale from 0 - 100 how much the client feels that he/she has recovered from his/her stroke.

    Time frame: Change from Baseline immediately after the intervention

  5. independent living skills

    Changes will be measured by Instrumental Activities of Daily Living (IADL) Scale. There are eight domains of function measured with the Lawton IADL scale. Clients are scored according to their highest level of functioning in that category. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men.

    Time frame: Change from Baseline immediately after the intervention

  6. NeuroTrax

    computerized cognitive evaluation battery. each outcome parameter will be normalized and fit to an IQ-like scale (mean=100, STD=15), according to the participants' age and education.

    Time frame: at baseline, 3 months

  7. MoCA

    Montreal Cognitive Assessment (MoCA). The maximum MoCA score is 30 points, with a 1-point scoring correction for individuals with 12 years of education or less. A score of 26 or above is considered normal and a score lower than 26 has been considered to be the optimal cutoff point for diagnosis of cognitive impairment.

    Time frame: Change from Baseline immediately after the intervention

  8. CANTAB Cambridge Neuropsychological Test Automated Battery

    computerized cognitive evaluation battery test, divided into 2 tasks: 1- Multitasking test (MTT)- attention, reaction time and executive functions, Multitasking test Incongruency cost - A higher incongruency cost indicates that the subjects takes longer to process conflicting information. 2-Paired associated learning (PAL)- visual memory and new learning, PAL Number of Patterns Reached (0-8), PAL Total Errors (Adjusted) (0-64), PAL Total Attempts(0-64).

    Time frame: at baseline, 3 months

  9. MRI Imaging

    At each of the evaluations, patients will undergo structural and functional MRI scanning. Images will be acquired on Vida 3 Tesla Scanner, configured with a 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at Shamir medical center radiology department.

    Time frame: Change from Baseline immediately after the intervention

  10. fMRI Imaging

    Resting state fMRI(rsfMRI or R-fMRI)- a method of functional brain imaging that can be used to evaluate regional interactions that occur when a subject is not performing an explicit task. This resting brain activity is observed through changes in blood flow in the brain which creates what is referred to as a blood-oxygen-level dependent (BOLD) signal that can be measured using functional Magnetic Resonance Imaging (fMRI).

    Time frame: Change from Baseline immediately after the intervention

  11. Physical, Neurological and functional evaluation

    A general physical and neurological evaluation will be done. NIHSS - The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS), will be used as part of the neurological evaluation to objectively quantify the impairment caused by the stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4 .For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.

    Time frame: Change from Baseline immediately after the intervention

  12. electrical brain activity

    Quantitative EEG (qEEG) including task related EEG analysis. EEG analysis for each state within subject and between subjects will include frequency analysis (peak frequency and relative power), oscillations (proportions of the different bands alpha, beta, theta, delta activities) and power spectra distribution.

    Time frame: Change from Baseline immediately after the intervention

  13. Inflammatory cytokines 1

    blood tests will include Inflammatory markers: IL-1 (IL-1β): pg/mL

    Time frame: Change from Baseline immediately after the intervention

  14. Inflammatory cytokines 2

    blood tests will include Inflammatory markers: IL-6: pg/mL

    Time frame: Change from Baseline immediately after the intervention

  15. Inflammatory cytokines 3

    blood tests will include Inflammatory markers: Tumor necrosis factor-alpha (TNF-α): pg/mL

    Time frame: Change from Baseline immediately after the intervention

  16. Inflammatory cytokines 4

    blood tests will include Inflammatory markers: hsCRP (high-sensitivity C-reactive protein): mg/L

    Time frame: Change from Baseline immediately after the intervention

  17. Inflammatory cytokines 5

    blood tests will include Inflammatory markers: Exosomes: particles/mL (by NTA) or µg protein/mL (by protein assay)

    Time frame: Change from Baseline immediately after the intervention

  18. Inflammatory cytokines 6

    blood tests will include Inflammatory markers: Serum VEGF: pg/mL

    Time frame: Change from Baseline immediately after the intervention

  19. Inflammatory cytokines 7

    blood tests will include Inflammatory markers: Testosterone (serum): ng/dL or nmol/L

    Time frame: Change from Baseline immediately after the intervention

  20. Inflammatory cytokines 8

    blood tests will include Inflammatory markers: Estradiol (E2, serum): pg/mL or pmol/L

    Time frame: Change from Baseline immediately after the intervention

  21. Inflammatory cytokines 9

    blood tests will include Inflammatory markers: DHEA-S (serum): µg/dL (commonly) or µmol/L

    Time frame: Change from Baseline immediately after the intervention

  22. Inflammatory cytokines 10

    blood tests will include Inflammatory markers: Progesterone (serum): ng/mL or nmol/L

    Time frame: Change from Baseline immediately after the intervention

  23. Inflammatory cytokines 11

    blood tests will include Inflammatory markers: Cortisol (serum): µg/dL or nmol/L

    Time frame: Change from Baseline immediately after the intervention

  24. Inflammatory cytokines 12

    blood tests will include Inflammatory markers: Telomere length: kilobases (kb) or relative T/S ratio (qPCR, arbitrary units)

    Time frame: Change from Baseline immediately after the intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2030, 84 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 84 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Feb 20, 2026
StartActual
Nov 8, 2023
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2030
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07423273
Responsible party
Shay Efrati (MD, Assaf-Harofeh Medical Center) — Principal investigator
First posted
Feb 20, 2026
Start date
Nov 8, 2023
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Apr 17, 2026

Study contacts

Shai a Efrati, MD
Contact
efratishai@outlook.com
972549212866
Shai a Efrati, MD
principal investigator · Asaf-Harofhe MC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion